Webinar: The next generation of liquid biopsy testing
LiquidHALLMARK® testing advances cancer understanding and can help tailor treatment
Join us to learn how LiquidHALLMARK® liquid biopsy testing, offered by Mayo Clinic Laboratories in collaboration with Lucence, is revolutionizing cancer testing. This test provides physicians with rapid and comprehensive information to help guide more precise cancer therapy selection and potentially improve patient outcomes.
This webinar will give oncologists, associated healthcare professionals, and laboratory directors insight into how LiquidHALLMARK® uses next-generation sequencing to target both DNA and RNA circulating in the blood to help physicians better understand a patient’s cancer, offering data that may be unavailable from other commercially available liquid biopsy tests.
10/28/25
Save the date
LiquidHALLMARK®: The next generation of liquid biopsy testing
Webinar Information
Date: Tuesday, Oct. 28, 2025
Time: Noon–1 p.m. CDT
Location: Via Livestream
Presented by: Mayo Clinic Laboratories
Cost: None
Questions: Contact us at mcleducation@mayo.edu for more information.
Learning objectives
Upon completion of this activity, participants should be able to:
- Discuss how LiquidHALLMARK® is the next iteration of liquid biopsy, moving beyond circulating DNA-only approaches, combining circulating tumor RNA and DNA to potentially identify more actionable targets for treatment.
- Highlight how the innovative testing technologies used in LiquidHALLMARK® may improve the detection of multiple mutation types to potentially identify more treatment options.
- Discuss research demonstrating how LiquidHALLMARK® may offer advantages over other commercially available liquid biopsy testing.
Presenters
Chief Scientific Officer for Mayo Collaborative Services
Bio
Dr. Binnicker is the chief scientific officer of Mayo Clinic Laboratories, has served as the director of the Clinical Virology and Clinical Microbiology Molecular Laboratories, and is a professor of laboratory medicine and pathology at Mayo Clinic. As chief scientific officer, Dr. Binnicker spearheads the scientific endeavors of Mayo Clinic Laboratories and leads product research, design, and development initiatives. He also works closely with leaders in Mayo Clinic's Department of Laboratory Medicine and Pathology, with other independent clinical laboratories, and leading diagnostic manufacturers to provide advanced testing and pathology services for healthcare organizations.
Founder and CEO of Lucence
Bio
Dr. Min-Han Tan is a medical oncologist and clinical cancer geneticist who founded Lucence, a precision oncology company headquartered in Palo Alto, California, and Singapore. He pioneered the development of advanced liquid biopsy dual-barcoding technologies focusing on ctDNA and ctRNA for cancer detection and therapy personalization, with Lucence being the first company to secure Medicare coverage for ctDNA and ctRNA liquid biopsy. His mission is to make earlier, more accurate cancer diagnosis accessible worldwide, combining clinical insight with advances in sequencing chemistry.
Resources
Credit: LiquidHALLMARK® is a trademark or registered trademark of Lucence Health Inc. and/or its affiliates in the U.S. and other countries and is used under license.